Ignelzi Troy A. 4

What Happened

• Troy A. Ignelzi, a non-employee director of Contineum Therapeutics, was granted a derivative award on 2026-06-26 covering 19,000 shares. The Form 4 reports the grant as 19,000 shares @ $0.00 (derivative), reflecting an option award rather than an open-market purchase or sale.
• The filing does not report a cash value or post-transaction beneficial ownership on this Form 4. This is a routine board compensation award, not a sale.

Key Details

• Transaction date: 2026-06-26 (filed same day).
• Transaction type/code: A (Grant/Award of a derivative security — stock option).
• Shares/units granted: 19,000 (derivative).
• Reported price on form: $0.00 (the Form 4 records it as a derivative grant).
• Shares owned after transaction: Not specified on the provided filing.
• Footnote: Options granted under the Issuer’s 2024 Equity Incentive Plan per the Non‑Employee Director Compensation Program — each continuing non-employee director automatically receives an option for 19,000 shares after the annual meeting.
• Vesting: Option vests in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, subject to the director’s continuous service.

Context

• This is a typical non-employee director equity grant used for compensation; it is not an open-market purchase (which some investors read as a stronger bullish signal).
• The grant creates potential future upside if options vest and are exercised; the Form 4 here does not detail exercise price or immediate sale — it simply reports the award.